I
Ionis Pharmaceuticals Inc (IONS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$28.01
-1.05 (-3.61%)
Market Cap: $4.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ionis Pharmaceuticals Inc (IONS) Valuation Multiples
Ionis Pharmaceuticals (IONS) trades at 4.8x sales and 11.8x book value. Its P/S of 4.8x is below its 5-year median of 8.2x. Its forward P/E is 90.9x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 90.9x |
| Price to sales | 4.8x |
| Price to book | 11.8x |
| PEG | N/A |
| FCF yield | -13.2% |
Historical Medians
Against its 10-year medians, its P/S is 48.4% below 9.3x and its P/B is 18.0% above 10.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 4.8x | 8.2x | 9.3x |
| P/B | 11.8x | 11.6x | 10.0x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 5.7x in 2021 to 15.7x in 2016.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $79.11 | N/A | 13.4x | 26.2x |
| 2024 | $34.96 | N/A | 7.4x | 9.4x |
| 2023 | $50.59 | N/A | 9.3x | 24.8x |
| 2022 | $37.77 | N/A | 9.1x | 9.4x |
| 2021 | $30.43 | 62.1x | 5.7x | 6.3x |
| 2020 | $56.54 | N/A | 10.8x | 9.4x |
| 2019 | $60.41 | 27.5x | 7.8x | 6.3x |
| 2018 | $54.06 | N/A | 12.3x | 7.7x |
| 2017 | $50.30 | N/A | 12.2x | 19.3x |
| 2016 | $47.83 | N/A | 15.7x | 59.5x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IONS
What is IONS's forward P/E ratio?
Ionis Pharmaceuticals has a forward P/E ratio of 90.9x.
Is IONS stock overvalued?
GNG's valuation label for IONS is Undervalued.
What is IONS's price to sales ratio?
Ionis Pharmaceuticals has a price to sales ratio of 4.8x.
IONS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors